NOXXON’s SDF-1 inhibitor NOX-A12 completes Phase I

14-Dec-2011 - Germany

Noxxon Pharma announced the completion of Phase I single and multiple dose clinical trials of its SDF-1 inhibitor NOX-A12. In phase I studies with healthy volunteers single doses of NOX-A12 up to 10.8 mg/kg and daily doses up to 2 mg/kg for five days were found to be safe and well tolerated and resulted in dose-dependent mobilization of white blood cells and CD34+ cells as predicted by preclinical studies.

Based on compelling pre-clinical data in hematological and solid tumors, NOXXON believes that NOX-A12 has the potential to be developed for treatment of multiple oncology indications. Initiation of the first Phase IIa trial of NOX-A12 in a hematological tumor indication is planned early in 2012, subject to regulatory and ethics committee approvals.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances